Psoriasis Clinical Trial

A Study of Mirikizumab in Participants With Plaque Psoriasis

Summary

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab.

The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males and females with chronic plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy
Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at screening and first admission to the clinical site

Exclusion Criteria:

Pregnant or nursing (lactating)
History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
Have major surgery within 8 weeks prior to first admission to the clinical site or during the study
Have a history of lymphoma, leukemia, or any malignancy
Require treatment with the cocktail drugs within 14 days prior to the first administration of the drug cocktail through the end of Week 12 assessments
Have participated in any other study with mirikizumab

Study is for people with:

Psoriasis

Phase:

Phase 1

Estimated Enrollment:

29

Study ID:

NCT03718884

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Anaheim Clinical Trials, LLC
Anaheim California, 92801, United States
Avail Clinical Research LLC
DeLand Florida, 32720, United States
High Point Clinical Trials Center
High Point North Carolina, 27265, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 1

Estimated Enrollment:

29

Study ID:

NCT03718884

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.